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Acute kidney injury (AKI) is a major complication of cardiac
bypass surgery. We examined whether levels of liver fatty
acid-binding protein (L-FABP) can be an early biomarker for
ischemic injury by measuring this protein in the urine of 40
pediatric patients prior to and following cardiopulmonary
bypass surgery. AKI was defined as a 50% increase in the
serum creatinine from baseline, which was normally not seen
until 24–72 h after surgery. Enzyme-linked immunosorbent
assay analysis showed increased L-FABP levels (factored for
creatinine excretion) of about 94- and 45-fold at 4 and 12 h,
respectively, following surgery in the 21 patients who
developed AKI with western blot analysis, confirming L-FABP
identity. Univariate logistic regression analyses showed that
both bypass time and urinary L-FABP were significant
independent risk indicators for AKI. After excluding bypass
time from the model and using a stepwise multivariate
logistic regression analysis, urinary L-FABP levels at 4 h after
surgery were an independent risk indicator with the area
under the receiver-operating characteristic curve 0.810,
sensitivity 0.714, and specificity 0.684 for a 24-fold increase in
urinary L-FABP. Our study shows that urinary L-FABP levels
represent a sensitive and predictive early biomarker of AKI
after cardiac surgery.
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Acute kidney injury (AKI), previously referred to as acute
renal failure,1 is the damage inflicted to the kidney following
an insult such as ischemia. The incidence of AKI in children
following cardiac surgery is between 5 and 20%.2,3 Patients
who experience AKI following surgery are at a much higher
risk of complications and death.4 Even small degrees of renal
dysfunction are associated with increased mortality.5,6
Pediatric patients comprise an important population for
study, since they usually do not have significant comorbid-
ities such as hypertension, atherosclerosis, or diabetes, which
affect kidney function in adults. Furthermore, pediatric
patients with congenital heart disease undergoing elective
surgery are more amenable to study putative urinary
biomarkers of AKI, since the time at which renal ischemia
occurs after cardiopulmonary bypass (CPB) surgery is well-
defined, and these subjects can be studied prospectively for
the development of AKI.7
In clinical practice, the diagnosis of acute renal failure is
usually made by observing an increase in serial measurements
of serum creatinine. Unfortunately, serum creatinine is not a
sensitive biomarker and occurs only after the disease has
progressed. The pathophysiologic processes leading to and
following kidney injury activate inflammation, cell death,
tubular regeneration, and other responses. One measurable
result of these processes is a change in the abundance of
certain proteins in the urine. Previous studies using animal
models as well as human studies have contributed to our
knowledge about cytokines, brush border enzymes, plasma
proteins, and other injury-inducible molecules that appear in
the urine. A number of potential biomarkers of AKI post
cardiac surgery have been proposed including plasma neutro-
phil gelatinase-associated lipocalin (NGAL) and cystatin C, and
a urine panel consisting of NGAL, interleukin-18, and kidney
injury molecule-1.8 Proposed mechanisms for the presence of
these low molecular weight proteins in urine include (a)
increased systemic inflammation with increased filtration of
these proteins in the urine, (b) reduced reabsorption by the
damaged proximal tubule, and (c) increased secretion from
injured kidney cells into the luminal space.
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In recent studies, we have examined the role of human
liver fatty acid-binding protein (h-L-FABP) in AKI. L-FABP
is a 14-kDa protein normally expressed in human kidney,
and, more specifically, in the proximal convoluted and
straight tubules.9,10 In a model of cisplatin-induced AKI, we
previously demonstrated increased shedding of urinary
L-FABP within the first 24 h, whereas a rise in serum
creatinine was not detectable until after 72 h of cisplatin
treatment.11 In this study, we examined the potential of
urinary L-FABP as a biomarker of AKI in a human model,
namely pediatric patients undergoing cardiac surgery.
RESULTS
Changes in renal function
From 40 patients studied, 21 (52%) developed AKI within a
3-day period. Of these, serum creatinine rose 24–48 h after
CPB in 10 subjects, but in the other 11 patients the increase
occurred 48–72 h after the procedure. Figure 1 compares the
changes in serum creatinine in patients who did not develop
AKI with changes with those who developed AKI. As shown
in Figure 1, in 19 patients who did not develop AKI, serum
creatinine did not change significantly during the first 5 days
after cardiac surgery going from 0.52±0.03 at 0 h to
0.41±0.02 mg per 100 ml at day 5 after surgery. In contrast,
in subjects who developed AKI, serum creatinine increased
from 0.40±0.03 mg per 100 ml before surgery (0 h) to
0.77±mg per 100 ml at 48 h post cardiac surgery (Po0.01
when compared to serum creatinine in patients who did not
develop AKI). The rise in serum creatinine was sustained for
5 days, suggesting the presence of a sustained form of acute
tubular injury such as acute tubular necrosis. On the basis of
the primary outcome, we classified children into those with
and without AKI. Children who developed AKI tended to be
younger and had significantly longer CPB times and length of
hospital stay when compared with those who did not develop
AKI (Table 1).
Detection of urinary h-L-FABP after cardiac surgery
We performed analysis of urinary h-L-FABP in 40 children
who underwent cardiac surgery for correction of congenital
malformations. AKI, defined as more than 50% rise in serum
creatinine from baseline values, occurred in 21 subjects, but
the diagnosis was delayed by 24–72 h after surgery. As shown
in Figure 2, in 19 patients who did not develop AKI, a
significant increase in urinary h-L-FABP was noted from
36±18 ng mg1 before surgery to 360±104 ng mg1 at 4 h
post surgery, and 208±63 ng mg1 Cr at 12 h post surgery. In
contrast, subjects who subsequently developed AKI had a
much more dramatic increase in urinary h-L-FABP from
baseline levels before surgery of 20±4 to 1885±500 ng mg1
Cr at 4 h and 904±320 ng mg1 Cr at 12 h post cardiac
surgery.
Western blot analysis was also performed in urine samples
obtained from children who underwent CPB surgery using a
monoclonal antibody raised against h-L-FABP. As shown in
Figure 3, the presence of a single band corresponding to the
expected size (14 kDa) of h-L-FABP was primarily detected at
4 h but also with less intensity at 12 h after cardiac surgery,
only in urine samples obtained from children who did
develop AKI. Our western blots results parallel the findings of
enzyme-linked immunosorbent assay (ELISA) measure-
ments, indicating that in patients who developed AKI, there
is a substantial amount of urinary excretion of L-FABP at 4 h
after cardiopulmonary bypass, but the amount of L-FABP
was considerably lower at 12 h after cardiopulmonary bypass.
Urinary L-FABP levels predict the development of AKI post
cardiac surgery
Our series of analyses began with a Mann–Whitney U-test to
compare the 4-h post surgery from baseline mean difference
in L-FABP levels for AKI patients versus those patients
without AKI. The test resulted in a significant mean L-FABP
difference (P-value¼ 0.0007) between the AKI patients and
those patients without AKI, which supported our hypothesis
that at 4 h post surgery, L-FABP levels between the two
groups are highly significant in their mean differences from
baseline values. The predictability quality of L-FABP for AKI
was further explored with an additional compilation of
statistical methods.
Univariate logistic regression analyses were performed on
the following variables to determine their independent ability
to serve as risk indicators for AKI: age, gender, CPB time,
previous cardiac surgery, and L-FABP. The univariate logistic
regression analyses resulted in two significant independent
predictors of AKI: CPB time (P-value¼ 0.0043) and L-FABP
(P-value¼ 0.0265). The outcomes of the remaining variables
(age, gender, and previous cardiac surgery) were insignificant
as independent predictors of AKI. Correlation analyses were
performed with Spearman’s correlation coefficients to
determine the correlation between L-FABP and the following
clinical outcomes: percentage of change in serum creatinine
(d-creatinine) and length of hospital stay after surgery. This
analysis was performed using all patients, both AKI patients
and those patients without AKI, and included all time
points (baseline, 4 h post surgery, and 12 h post surgery)
for the variables of interest. Both correlation coefficients
were statistically significant: d-creatinine (r¼ 0.2617,
P-value¼ 0.0039) and length of hospital stay after surgery
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Figure 1 | Changes in serum creatinine (mean±s.e.) at various
time points after cardiac surgery in the non-AKI and AKI group.
*Po0.01 when serum creatinine is compared at various time points
between non-AKI and AKI patients.
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(r¼ 0.32093, P-value¼ 0.0004). Two identical correlation
analyses were also performed on the subset of patients at 4 h
and 12 h post cardiac surgery. At 4 h post cardiac surgery, the
correlation analysis results were as follows: d-creatinine
(r¼ 0.46544, P-value¼ 0.0025) and length of hospital stay
after surgery (r¼ 0.57825, P-valueo0.0001). At 12 h post
cardiac surgery, the correlation analysis results were as
follows: d-creatinine (r¼ 0.47945, P-value¼ 0.0017) and
length of hospital stay after surgery (r¼ 0.53568, P-
value¼ 0.0004). The correlation between L-FABP and both
variables (d-creatinine and length of hospital stay after
surgery) were statistically significant when taking all time
points into account as well as at both 4 h and 12 h post
cardiac surgery. Figure 4 displays the receiver-operating
characteristic (ROC) curve for L-FABP at 4 h post cardiac
surgery. This figure displays each underlying L-FABP
cutpoint value encompassing the ROC curve along with the
resulting ROC curve. The area under the L-FABP ROC curve
at 4 h post surgery was 0.810. Derived sensitivities and
specificities for a selection of specified L-FABP cutpoint
concentration levels (211, 350, 486, 592, and 1023) are listed
in Table 2. A cutoff value of 486 ng mg1 Cr yields both good
sensitivity (0.7142) and specificity (0.6842) levels of AKI at
4 h post cardiac surgery.
A stepwise logistic regression selection procedure was used
to determine the most parsimonious model given a set of
potential variables for predicting AKI. This analysis was
performed on the 4-h post cardiac surgery data, and potential
variables for this model included age, gender, CPB time,
previous cardiac surgery, and L-FABP. The resulting selected
model revealed CPB time (P-value¼ 0.0043), as the most
powerful independent predictor of AKI in our cohort. When
a secondary stepwise logistic regression selection procedure
Table 1 | Patients’s characteristics and clinical outcomes
Without acute
kidney injury (n=19)
Acute kidney
injury (n=21) P
Demographics
Age (years) 4.3 (1.3) 2.7 (0.8) 0.233
Boys 12 9
Girls 7 12
White ethnic origin 12 21
African American 7 0
Clinical outcomes
Previous heart surgery 5 8
Cardiopulmonary bypass time (min) 82 (9.7) 145 (12.3) 0.00025
Change in serum creatinine (%) 14.7 (3.4) 190 (39) 0.00008
Length of hospital stay 6.1 (1.4) 20.1 (3.4) 0.005
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Figure 2 | Changes in urinary L-FABP concentrations at various
time points after CPB surgery in non-AKI and AKI patients. Error
bars are ±s.e. *Po0.01 when urinary L-FABP levels at 4 and 12 h post
cardiac surgery are compared between non-AKI and AKI patients.
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Figure 3 | Representative western blot of urine samples obtained
at various time points after CPB from a patient who did not
develop AKI and a patient who subsequently developed AKI.
Blots were probed with a monoclonal antibody to h-L-FABP.
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Figure 4 | ROC curve analysis for urinary L-FABP at 4 h post
cardiac surgery.
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was performed including the previous variables while
excluding CPB time, this resulted in a most parsimonious
model including only the single variable L-FABP (P-value¼
0.0265) as a predictor for AKI.
Changes in microalbuminuria
Microalbuminuria was slightly increased in patients who did
not develop AKI from levels before surgery of 22.1±5.7 to
47.8±10.1 mg mg1 Cr at 4 h and 72.6±15.9 mg mg1 Cr at
12 h post surgery. In contrast, we detected a significant effect
with respect to microalbuminuria in the AKI group.
Microalbuminuria increased from levels before surgery of
15.2±4.5 to 328.3±68.3 mg mg1 Cr at 4 h and 586.4±
120.3 mg mg1 Cr at 12 h, in those patients who developed
AKI. These results are shown in Figure 5.
Changes in urinary NGAL levels
Urinary NGAL, a validated biomarker for AKI,12 was also
measured in this cohort of patients. As shown in Figure 6,
urinary NGAL levels were slightly increased in patients who
did not develop AKI from levels before surgery of 3.7±0.9 to
32.8±6.1 ng mg1 Cr at 4 h and 21.7±3.8 ng mg1 Cr at 12 h
post surgery. In contrast, we detected a significant effect with
respect to urinary NGAL levels in the AKI group. Urinary
NGAL increased from levels before surgery of 8.0±1.7 to
491.0±82.3 ng mg1 Cr at 4 h and 330±39.8 ng mg1 Cr at
12 h, in those patients who developed AKI. We utilized these
measurements to determine the sensitivity and specificity for
NGAL at different cutoff values for this identical cohort of
patients by constructing a conventional ROC curve. The
corresponding area under the curve was calculated for the
ROC curve, which yielded a quantifier for the quality of
NGAL as a biomarker for AKI. Possible area under the curve
values can range from 0 to 1.0, where a value of 1.0 signifies a
perfect biomarker and a value of 0.5 is no better than one
would expect under random chance. Figure 7 displays the
ROC curve for NGAL at 4 h post cardiac surgery. This figure
displays each underlying NGAL cutpoint value encompassing
the ROC curve along with the resulting ROC curve. The area
under the NGAL ROC curve at 4 h post surgery was 1.000,
which coincides with the superb, previously published NGAL
Table 2 | L-FABP and NGAL test characteristics at different
cutoff values
Sensitivity Specificity
Cutpoints for L-FABP (ng mg1 Cr)
211 0.9520 0.6316
350 0.8095 0.6316
486 0.7142 0.6842
592 0.6666 0.7895
1023 0.5238 0.8947
Cutpoints for NGAL (ng mg1 Cr)
85 1.0000 0.8947
96 1.0000 0.9474
100 1.0000 1.0000
122 0.9524 1.0000
146 0.9048 1.0000
L-FABP, liver fatty acid-binding protein; NGAL, neutrophil gelatinase-associated
lipocalin.
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Figure 5 | Changes in microalbuminuria at various time points
after CPB surgery in non-AKI and AKI patients. Error bars are±s.e.
*Po0.01 when urinary levels of microalbumin are compared between
non-AKI and AKI patients.
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Figure 6 | Changes in urinary NGAL concentrations (mean±s.e.)
at various time points after cardiac surgery in the non-AKI and
AKI patients. *Po0.01 when urinary NGAL levels are compared
between non-AKI and AKI patients.
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surgery.
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results.12 Derived sensitivities and specificities for a selection
of specified NGAL cutpoint concentration levels are listed in
Table 2; however, a cutoff value of 100 ng mg1 Cr yielded
both perfect sensitivity (1.000) and specificity (1.000) levels
of AKI.
Changes in serum L-FABP levels
Because we did not have a large amount of serum samples
from our original group of 40 patients, serum L-FABP levels
were measured in a total of 16 patients: 8 with AKI and 8
without AKI. Figure 8 presents the data in serum L-FABP
levels measured at 0, 4, and 12 h after cardiac surgery. In three
out of those eight patients who developed AKI post cardiac
surgery, there was significant liver injury determined by an
elevation in serum ALT, with levels that varied between 500
and 3000 IU in those three patients. Figure 8 shows that in
patients who developed AKI post cardiac surgery, there was a
significant increase in serum L-FABP levels at 12 h post
cardiac surgery (410.5±120.9 ng ml1), when compared to
serum L-FABP levels measured in patients who did not
develop AKI (28.5±8 ng ml1). In contrast, urinary L-FABP
levels measured in this same subset of patients who developed
AKI was increased within the first 4 h post surgery from
baseline levels of 9.15±1.8 to 791±349 ng mg1 Cr at 4 h
post surgery, while urinary levels did not rise in patients who
did not develop AKI. These findings suggest that increased
urinary L-FABP levels at 4 h post cardiac surgery in AKI
patients, rather than just reflecting increased filtration of high
serum levels represent an increased in the shedding of
proximal tubule L-FABP.
DISCUSSION
Our study is the first one to demonstrate that urinary
excretion of h-L-FABP in pediatric patients undergoing
cardiac surgery is significantly increased within the first 4 h of
cardiac surgery, and precedes the rise on serum creatinine not
seen until 24–72 h post cardiac surgery, in those patients who
developed AKI. To evaluate the clinical significance of urinary
L-FABP as a biomarker in renal disease, a two-step sandwich
ELISA method using monoclonal antibodies to h-L-FABP
protein was established for quantification of h-L-FABP in
urine.13,14 There is only one previous study that examined the
role of urinary L-FABP in contrast dye-induced AKI.15 In
that study, the investigators found that urinary L-FABP levels
were significantly increased only in those patients who
developed AKI post contrast dye. One important difference
between that study and our study in cardiac surgery patients
is that urinary L-FABP levels are much higher in cardiac
surgery patients who developed AKI. The discrepancy in the
urinary levels of L-FABP between two distinct types of AKI
we believe relates to the presence of ischemic injury in
patients undergoing cardiac surgery. As demonstrated in a
recent study done in Japan,16 urinary L-FABP levels
correlated well to the level of renal ischemia (peritubular
capillary ischemia). Therefore, we believe that the degree of
ischemia seen in patients undergoing CPB is probably not
seen in patients receiving contrast media. Future studies
using this urinary L-FABP assay should allow us to further
examine these potential differences, as well as the cutoff levels
of urinary L-FABP in various forms of AKI.
Our present results lend support to the concept that
urinary L-FABP levels can serve clinically as a predictive
biomarker of AKI. Other clinical studies have also shown that
increased presence of urinary L-FABP can be an excellent
clinical marker to predict and monitor the progression of
renal disease.17–23 Kamijo et al.13 reported that various
stresses such as massive proteinuria and ischemia induce free
fatty acid overload in the proximal tubule and exacerbate
tubulointerstitial damage. They also reported14 that urinary
L-FABP levels were more sensitive than proteinuria in
predicting the progression of CKD, thereby indicating that
urinary L-FABP is a useful clinical biomarker in the
monitoring of CKD. In addition, this group reported that
the estimated contribution of serum L-FABP to urinary
L-FABP in CKD was only 3±3%, suggesting that serum
L-FABP levels do not influence urinary L-FABP levels.
Using h-L-FABP transgenic mice and the model of
unilateral ureteral obstruction, Kamijo et al.23 showed that
h-L-FABP expressed in the proximal tubules, was upregulated
in the unilateral ureteral obstruction model of AKI, and that
this increased expression likely suppressed the development
of tubulointerstitial damage. On the basis of those observa-
tions, these investigators concluded that renal L-FABP is
likely to be an effective endogenous antioxidant. In more
recent studies using h-L-FABP transgenic mice, we demon-
strated that cisplatin treatment induced increased shedding
of urinary h-L-FABP within the first 24 h and preceded the
rise on serum creatinine not seen until 72 h after CP
treatment. L-FABPs play a key role in the transport of fatty
acids to organelles such as mitochondria and peroxisomes for
oxidation and also involved in the regulation of gene
expression and cell differentiation.24–27 Moreover, L-FABP
has high affinity and capacity to bind long-chain fatty acid
oxidation products and may be an effective endogenous
antioxidant.
In addition to urinary L-FABP, our study also shows that
the presence of microalbuminuria and increased urinary
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Figure 8 | Changes in serum L-FABP concentrations at various
time points after CPB surgery in non-AKI and AKI patients. Error
bars are±s.e. *Po0.01 when serum L-FABP levels are compared
between non-AKI and AKI patients.
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NGAL represent additional sensitive biomarkers of AKI
during cardiac surgery. We also find that in very few patients
who developed AKI post cardiac surgery, serum L-FABP was
elevated at 12 but not at 4 h post cardiac surgery, while in
these same patients urinary L-FABP was significantly elevated
at 4 h post cardiac surgery.
The cause of the elevation in serum L-FABP at 12 h post
cardiac surgery cannot be entirely explained by the presence
of liver injury post cardiac surgery. Furthermore, our results
suggest that increased urinary L-FABP levels at 4 h post
cardiac surgery in AKI patients, rather than just reflecting
increased filtration of high serum L-FABP levels, represent an
increased in the shedding of proximal tubule L-FABP. Further
studies will be needed to determine the mechanisms of
increased shedding of proximal tubule L-FABP during
cardiac surgery.
Our study has several strengths. First, we prospectively
recruited a relatively homogeneous cohort of pediatric
subjects in whom the only obvious etiology for AKI would
be the result of cardiac surgery. These patients comprise an
important population for the study of AKI biomarkers, since
they do not exhibit common comorbid variables such as
diabetes, hypertension, atherosclerosis, and nephrotoxin use.
Second, all subjects started with normal kidney function and
low levels of h-L-FABP in the urine. The study design allowed
for the precise temporal definition of altered h-L-FABP
concentrations following cardiac surgery, and a direct
comparison with changes in serum creatinine, the current
gold standard for the definition of AKI. Our results indicate
that h-L-FABP is a powerful early biomarker of AKI that
precedes the increase in serum creatinine by several hours
to days. The magnitude of rise supports the notion that
h-L-FABP is a highly discriminatory biomarker with a wide
dynamic range and cutoff values that allow for risk
stratification. Indeed, we found that other variables such as
patient demographics and previous cardiac surgery were not
predictive of AKI, and could not be used for risk assessment
in our cohort. Third, we adjusted for potential changes in
urinary biomarker concentration by correcting urinary
h-L-FABP concentrations using urinary creatinine. Fourth,
our results demonstrate that early urinary h-L-FABP levels
were not only highly predictive of AKI, but were also
associated with important clinical outcomes such as severity
of AKI (d-creatinine) and length of hospital stay.
Our results show significant increases in urinary L-FABP
and NGAL levels in children who develop AKI after cardiac
surgery. This suggests a common mechanism of proximal
tubule injury. Previous studies have shown that after
secretion into the tubular lumen, these two lipocalins are
reabsorbed by the proximal tubule via megalin-dependent
endocytosis.28,29 Therefore, it is possible that early kidney
injury resulting from CPB could cause disruption of megalin-
dependent endocytosis in the renal proximal tubule, resulting
in the loss of urinary NGAL and L-FABP. A similar
mechanism of proximal tubule cell injury was previously
described in the animal model of cisplatin-induced AKI.30
This study has limitations. First, it is a single-center pilot
study of pediatric subjects with congenital heart defects
undergoing elective cardiac surgery. Our results will need to
be validated in a larger population, including adults with the
usual confounding variables and comorbid conditions that
normally accumulate with increasing age. Second, ours was a
cohort with relatively pristine kidney function, and it will be
important to confirm our findings in documented high-risk
settings such as preexisting kidney dysfunction, diabetes
mellitus, volume depletion, concomitant nephrotoxic drug
use, and the hemodynamically compromised patient. Third,
in addition to h-L-FABP, simultaneous examination of
several potential urinary biomarkers as predictors of AKI
will be crucial. Other highly promising urinary candidates
include NGAL, kidney injury molecule-1, and interleukin-18.
It is likely that not one single biomarker such as h-L-FABP,
but a collection of strategically selected candidates, will
provide the panel for early and rapid diagnosis of AKI.
Fourth, it will be important to partner with industry, to
convert our current research-based assays into standardized
commercial platforms and point-of-care kits for validation in
multicenter trials, and for ultimate clinical utility.
MATERIALS AND METHODS
Patient population
Urine samples were prospectively obtained from 40 patients who
underwent cardiac surgery using CPB at Cincinnati Children’s
Hospital for the correction or palliation of congenital cardiac
defects. Exclusion criteria included preexisting renal insufficiency,
diabetes mellitus, and concomitant nephrotoxic drug use. AKI
was defined as a 50% increase in serum creatinine from baseline,
which typically occurred 48–72 h after surgery. For each patient,
three urine samples were obtained that corresponded to time
0 h (presurgery), 4 h post surgery, and 12 h post surgery. The
research protocol for collection of these samples was approved
by the Cincinnati Children’s Medical Institutional Review Board,
and blind analysis of these de-identified urine samples was also
approved by the Institutional Review Board of the University of
Arkansas for Medical Sciences. All samples were stored at 801C
prior to analysis.
ELISA for quantitation of urinary L-FABP
The levels of serum and urinary h-L-FABP were measured using
h-L-FABP ELISA kit (CMIC Co. Ltd, Tokyo, Japan).13,31,32 The
h-L-FABP protein standard or 50 ml of urine or serum samples
obtained from patients were first treated with a pretreatment
solution, and then transferred into a 96-well plate coated with a
monoclonal antibody against h-L-FABP. After 1 h incubation, the
wells were washed and then the conjugate reagent added as
secondary antibody for another hour to allow for binding of the
h-L-FABP antigen, the immobilized antibody, and the conjugate
antibody. After incubation, the plate was washed and a substrate
solution for the immunoperoxidase reaction added for 30 min to
develop a color based on the amount of h-L-FABP antigen present in
the samples. The reaction was stopped using a stop solution. Urinary
h-L-FABP concentration was quantitated by measuring the absor-
bance of each well at 492 nm. Urinary h-L-FABP level was expressed
as the ratio of the urinary h-L-FABP in ng mg1 urinary creatinine
to adjust for changes in urinary concentration.
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Measurement of microalbumin
Urinary microalbumin was measured by standard immunonephe-
lometry (BN Prospec System; Dade Behring Marburg GMBH,
Deerfield, IL, USA).
ELISA for quantitation of urinary NGAL
The urine NGAL ELISA was performed using an established and
validated assay as previously described.12 Briefly, microtiter plates
precoated with a mouse monoclonal antibody raised against h-
NGAL no. HYB211-05; AntibodyShop, Gentofte, Denmark) were
blocked with buffer containing 1% bovine serum albumin, coated
with 100ml of samples (urine) or standards (NGAL concentrations
ranging from 1 to 1000 ng ml1), and incubated with a biotinylated
monoclonal antibody against h-NGAL (no. HYB211-01B, Antibody-
Shop) followed by avidin-conjugated HRP (Dako, Carpinteria, CA,
USA). TMB substrate (BD Biosciences, San Jose, CA, USA) was
added for color development, which was read after 30 min at 450 nm
with a microplate reader (Benchmark Plus, Bio-Rad, Hercules, CA,
USA). All measurements were made in triplicate. The inter- and
intra-assay coefficient variations were o5% for batched samples
analyzed on the same day, ando10% for the same sample measured
6 months apart. The laboratory investigators were blinded to the
sample sources and clinical outcomes until the end of the study.
Immunoblotting
Equal volumes (20ml) of urine were boiled for 5 min in denaturing
buffer and separated on a 12% sodium dodecyl sulfate-polyacryla-
mide gel electrophoresis and then electroblotted to a nitrocellulose
membrane. The membrane was blocked for 1 h with 5% nonfat
dried milk in TBS-T buffer (20 mM Tris, pH 7.6, 100 mM NaCl,
0.1% Tween 20) at room temperature. The membrane was then
incubated overnight at 41C with a mouse monoclonal h-L-FABP
antibody (1:2000 dilution) in TBS-T buffer containing in 5% nonfat
dried milk. After washing three times with TBS-T buffer, the
membranes were incubated with a horseradish peroxidase-con-
jugated goat anti-mouse IgG as a second antibody (1:5000 dilution)
for 1 h at room temperature. Proteins were visualized by using
enzyme-linked enhanced chemiluminescence (Amersham, Arlington
Heights, IL, USA).
Statistical analysis
A collective set of statistical methods was used to investigate the
predictive quality of h-L-FABP as a biomarker for AKI. A
Mann–Whitney U-test, a nonparametric alternative to an indepen-
dent two-sample t-test, was used to compare the difference between
h-L-FABP mean levels in AKI patients and those patients without
AKI. Both univariate logistic regression analyses and a stepwise
logistic regression analysis were used as exploratory measures for
variable predictability of AKI. Potential independent predictor
variables included age, gender, CPB time, previous cardiac surgery,
and h-L-FABP levels. Furthermore, correlation analyses were
conducted by using Spearman’s correlation coefficients at post
cardiac surgery time points 4 and 12 h as well as an analysis
including all time points (baseline, 4 h post surgery, 12 h post
surgery). To measure the sensitivity and specificity for L-FABP and
NGAL at different cutoff values, a conventional ROC curve was
constructed. The area under the curve was calculated for the ROC
curve to establish the quality of L-FABP and NGAL as biomarkers
for AKI. Possible area under the curve values can range from 0 to
1.0, where a value of 1.0 signifies a perfect biomarker and a value of
0.5 is no better than one would expect under random chance. Race
was not included as a factor in any of our analyses due to a complete
separation between those patients with and without AKI. A 0.05
significance level was used to determine statistical significance. SAS
version 9.1 was used to compute all statistical analyses and figures.
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